{"id":"W4317989607","doi":"10.1182/bloodadvances.2022009389","title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"H. Lundbeck A/S; Incyte; Teva Pharmaceutical Industries; Genentech; Celgene; University of Southampton; Karyopharm Therapeutics; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Ibrutinib; Medicine; Oncology; Internal medicine; CHOP; Clinical trial; Bruton's tyrosine kinase; Phases of clinical research; Immunology; Lymphoma; Cancer research; Leukemia; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001372707,0.0001611628,0.0005777559,0.0002277901,0.00003963854,0.00002398649,0.0001790113,0.0001124721,0.00003729696],"category_scores_gemma":[0.001257552,0.00009969972,0.0001306722,0.0008957513,0.0003005247,0.0001415934,0.00008376645,0.0003377808,0.00001000527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006124062,"about_ca_system_score_gemma":0.002654787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000711789,"about_ca_topic_score_gemma":0.0001072047,"domain_scores_codex":[0.9978477,0.0002791626,0.0006727877,0.0003419761,0.0004239057,0.0004344135],"domain_scores_gemma":[0.9976969,0.001652017,0.0001354449,0.0003574935,0.00004535005,0.0001127378],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3612932,0.01659539,0.2136792,0.001828435,0.001118491,0.01045359,0.01879082,0.001335231,0.02705361,0.0001477169,0.00428058,0.3434237],"study_design_scores_gemma":[0.9544508,0.003815264,0.02596261,0.0007149652,0.0001443352,0.0001776851,0.001184327,0.009035045,0.002207386,0.0001710582,0.001915957,0.0002205307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960694,0.00197502,0.000002113125,0.0001729655,0.00009398707,0.0008641564,0.00002149866,0.00003683364,0.0007640442],"genre_scores_gemma":[0.9981859,0.0012284,0.00009044827,0.00004542318,0.0002615776,0.00003894972,0.00002614984,0.00001831881,0.0001048802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5931576,"threshold_uncertainty_score":0.4709479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07110328231378076,"score_gpt":0.4849904588907227,"score_spread":0.413887176576942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}